Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wynn Resorts, Limited (WYNN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Wynn Resorts (WYNN) trades at $99.77, up 0.95% on the day, but remains 13.4% down year-to-date amid bearish technical signals. The company reported Q1 2026 EPS of $1.25, meeting expectations, but has missed estimates in three of the last four quarters. Revenue growth continues with $7.14B in 2025, though net margins have compressed from 11.17% in 2023 to 4.58% in 2025. High debt levels persist with $10.50B long-term debt, while analyst consensus remains strongly bullish with a $134.60 price target.

The outlook is mixed: strong analyst support and luxury market positioning offer upside potential, but margin pressure, high leverage, and recent earnings misses present significant risks. The stock's current valuation at 28.59 P/E appears stretched given declining profitability, making execution on future growth critical for investor returns.